FDA Delays Decision on Bristol Myers and 2seventy Bio's CAR-T Therapy
TL;DR
The FDA has delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio's CAR-T cell therapy for multiple myeloma in earlier lines of treatment. The regulator plans to hold a public meeting with outside experts to discuss the therapy, which was originally expected to receive a decision by December 16. Currently, the therapy is approved for multiple myeloma patients who have previously had four or more lines of treatment.
Topics:businesshealthcare#2seventy-bio#bristol-myers-squibb#car-t-therapy#fda#healthcare#multiple-myeloma
- Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision Endpoints News
- Bristol Myers Squibb (NYSE:BMY) Falls after FDA Delays Action on Cancer Therapy - TipRanks.com TipRanks
- Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma Bristol-Myers Squibb
- US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy Reuters
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News